Intercept Pharmaceuticals (ICPT) PT Raised to $221 at BMO Capital

February 24, 2017 8:26 AM EST Send to a Friend
BMO Capital raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $221.00 (from $198.00) while maintaining a Outperform rating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login